Type 1 gastric neuroendocrine tumor
Conditions
Interventions
Experimental group:Shumu Liujunzi Decoction combined with Endoscopic Treatment
Controlled group:Placebo combined with Endoscopic Treatment
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1)Age = 18 years old (2)According to the WHO (5th) classification and grading standards for gastrointestinal / hepatobiliary pancreatic neuroendocrine tumors in 2019, combined with the CSCO guidelines for diagnosis and treatment of neuroendocrine tumors (2021 Edition), type 1 g-nets were diagnosed: gastric neuroendocrine tumors (netg1 or netg2) with good differentiation were pathologically diagnosed. Serum gastrin was elevated, gastric parietal cell antibodies were positive, internal factor antibodies were positive, vitamin B12 was deficient, and gastroscopy showed multiple and polypoid lesions, Gastroscopy and pathology suggested (autoimmune) atrophic gastritis, HP (-), exclusion type 2 g-nets. (3)Informed consent was signed.
Exclusion criteria
Exclusion criteria: (1)Have a history of malignant tumors of other parts and types (2)Have a history of gastric surgery (3)Taking proton pump inhibitors and H2 receptor blockers for at least 3 months (4)Combined with serious diseases that affect the evaluation of the study (5)Participated in clinical research of other drugs within 3 months before participating in the project (6)Patients in preparation for pregnancy (7)Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence rate of the Tumor; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of pathological grade in gastroscopic biopsy;Changes of endoscopic grading of atrophic gastritis;Improvement degree of EORTCQLQ–GI.NET21 scale;Recurrence time of the Tumor;Improvement degree of QLQ-C30 scale;Improvement of TCM symptom scores; | — |
Countries
China
Contacts
Public ContactTan Huangying
Outcome results
None listed